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S100B has been linked to glial pathology in several psychiatric disorders. Previous
studies found higher S100B serum levels in patients with schizophrenia compared
to healthy controls, and a number of covariates influencing the size of this effect
have been proposed in the literature. Here, we conducted a meta-analysis and meta-
regression analysis on alterations of serum S100B in schizophrenia in comparison with
healthy control subjects. The meta-analysis followed the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA) statement to guarantee a high quality
and reproducibility. With strict inclusion criteria 19 original studies could be included
in the quantitative meta-analysis, comprising a total of 766 patients and 607 healthy
control subjects. The meta-analysis confirmed higher values of the glial serum marker
S100B in schizophrenia if compared with control subjects. Meta-regression analyses
revealed significant effects of illness duration and clinical symptomatology, in particular
the total score of the Positive and Negative Syndrome Scale (PANSS), on serum
S100B levels in schizophrenia. In sum, results confirm glial pathology in schizophrenia
that is modulated by illness duration and related to clinical symptomatology. Further
studies are needed to investigate mechanisms and mediating factors related to these
findings.
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INTRODUCTION
S100B is a calcium-binding protein which can be secreted by astroglia and oligodendroglia
(e.g., Donato, 2001; Steiner et al., 2007, 2008; Donato et al., 2009). In the brain, it is
generally assumed to be neurotrophic in nanomolar concentrations due to its activation of
neural growth factor pathways and up-regulation of anti-apoptotic factors. In micromolar
concentrations however, it becomes neurotoxic, interacting with pro-inflammatory cytokines
like interleukin (IL)-1, IL-6, tumor necrosis factor (TNF) alpha, up-regulating the expression of
pro-apoptotic factors as well as inducing nitric oxide synthase and cyclooxygenase 2 expression
(Donato, 2001; Van Eldik and Wainwright, 2003; Donato et al., 2009; Bianchi et al., 2010).
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Thus, S100B has been linked to the presence of inflammatory
processes in the brain, either after injury or due to primary
inflammation (Sen and Belli, 2007). Furthermore, certain
neuropsychiatric disorders, among them schizophrenia,
have been found to be associated with elevated serum and
cerebrospinal fluid (CSF) levels of S100B (e.g., Rothermundt
et al., 2004a), thus implying immunoreactive glial processes
as important in either their genesis or progression. Although
serum S100B might be associated with other conditions
such as blood-brain barrier disruption, weight changes
or neurological diseases, S100B changes in schizophrenia
are lower than would be expected in neurological diseases
with brain injury (Schroeter et al., 2009; Steiner et al.,
2010b).
Here, we conducted a systematic and quantitative meta-
analysis of changes in serum S100B in schizophrenia, which
extends former meta-analyses on this issue (Schroeter et al.,
2003, 2009; Schroeter and Steiner, 2009; Aleksovska et al.,
2014) by including further studies and accordingly, increasing
statistical power and evidence. Based on previous studies, we
hypothesized higher S100B in schizophrenia when compared
to healthy controls. Additionally, we investigated effects of
medication and applied meta-regression analyses to investigate
effects of clinical parameters on serum S100B. We hypothesized
here an association of S100B with the duration of illness
as recent studies have shown progression of astrocytes’
dystrophy/swelling and of oligodendrocyte-related disturbances
of cerebral connectivity with duration of illness (Kolomeets
and Uranova, 2010; Bernstein et al., 2015; Yao et al., 2015).
Moreover, we hypothesized an association of S100B with
negative symptoms as shown in previous studies (Rothermundt
et al., 2001, 2004b; Schroeter et al., 2003; Schmitt et al.,
2005).
MATERIALS AND METHODS
General Study Selection Criteria
The meta-analysis was conducted according to the Preferred
Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA) statement to guarantee a high quality and
reproducibility of the meta-analysis (Moher et al., 2009).
The search terms [S100 or S-100] as well as [S100B or S-100B]
and [schizophrenia] were used to identify original studies
published between 1970 and October 2015 in PubMed,
Web of Science, Ovid and Scopus databases. Studies had to
meet the following inclusion criteria: peer-reviewed, patients
diagnosed with schizophrenia according to International
Classification of Diseases (ICD-10) and/or Diagnostic and
Statistical Manual of Mental Disorders (DSM-IV) standards,
original studies, comparison with age-matched control
subjects. Studies were checked for eligibility and selected by
two persons (KS and MP). We pooled plasma and serum
studies under the assumption that calculation of effect sizes
normalizes absolute differences between patients and control
subjects and thus, eliminates differences in methodological
approaches.
Data Synthesis
S100B levels were extracted from the articles along with
information on additional covariates as examined and reported
by the investigators. In case exact values were not given in
the article or if data were only illustrated in plots, authors
were contacted to obtain detailed information. To adjust for
systematic measurement effects in the several original studies, we
calculated effect sizes. Standard deviations (SD) were calculated
from standard error of the mean (SEM) using the formula
SD = SEM∗
√
n if necessary. Following a conservative approach,
the Comprehensive Meta-Analysis software package (versions 2
and 3, Biostat, Inc., Englewood, NJ, USA1) was then used to
compute Hedges’ g corrected for small sample size effects under
a random effects model, with effect sizes of 0.2 signifying a small,
0.5 a medium, and 0.8 and larger a strong effect (Cohen, 1988;
Lakens, 2013). This software has already been used in several
other meta-analytic studies (e.g., Gami et al., 2007; Hofmann and
Smits, 2008; Howren et al., 2009; Leucht et al., 2009).
Besides investigating differences between patients with
schizophrenia and healthy control subjects per se, we conducted
subgroup analyses comparing drug-free with medicated patients.
Additionally, we checked for possible effects of clinical covariates
on effect size via meta-regression, applying the Method of
Moments (DerSimonian and Laird, 1986). Potential covariates
included illness duration, age at onset of the disorder, male-
to-female ratio, severity of clinical symptoms as measured
with the clinical symptom scales Brief Psychiatric Rating Scale
(BPRS, total score), and Positive And Negative Syndrome
Scale (PANSS, total score as well as positive, negative and
general psychopathology subscores), as well as an index of
risk of bias for cross-sectional studies published in Polyakova
et al. (2015). Note that mean age was not included in this
analysis, because in each of the included studies schizophrenia
patients were compared with age-matched control subjects (see
inclusion criteria). Body mass index (BMI), although of interest
due to its potential effects on serum S100B (e.g., see Steiner
et al., 2010a,b, 2014), could not yet be analyzed as a covariate
due to lack of a sufficient number of studies reporting this
measure.
RESULTS
Identified Studies
Details of the study selection process are illustrated in the
PRISMA flow diagram in Figure 1. The search in PubMed
yielded a total of 121 results, while Web of Science offered
149 hits, Ovid 42 and Scopus 109 results. Following exclusion
of reviews, conference abstracts, oncology related papers, book
chapters, errata as well as texts written in languages other
than English via database settings, 312 studies remained.
Further elimination by title of post-mortem, in vitro, animal
and genetic studies, studies investigating S100B in CSF only
or studies with patients other than schizophrenia resulted
in 38 articles in PubMed, 39 in Web of Science, 21 in
Ovid, and 43 in Scopus databases. The abstracts of these
1https://www.meta-analysis.com/
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FIGURE 1 | Flow diagram illustrating the database search process according to Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA). CSF, cerebrospinal fluid; DSM-IV, Diagnostic and Statistical Manual of Mental Disorders IV; ICD-10, International Statistical Classification
of Diseases and Related Health Problems 10; SD, standard deviation.
141 articles were screened for eligibility, leading to a total of
80 articles which were then checked for duplicates, resulting in
27 full-text articles to be examined for meeting the inclusion
criteria. Corresponding authors were contacted in cases where
S100B levels or patient characteristics for schizophrenia-only
patients were not explicitly stated in the original article. As
authors did not reply, another two studies were excluded
(van der Leeuw et al., 2013; Xiong et al., 2014). This
resulted in an overall number of 19 original studies to be
included in the quantitative meta-analysis, comprising a total of
766 patients and 607 healthy control subjects. Included studies
and clinical characteristics of the study population are reported
in Table 1.
Main Effects
Across all included studies comparing patients suffering from
schizophrenia with control subjects, Hedges’ g amounted to
0.925, indicating a higher level of S100B in schizophrenia patients
compared to healthy controls (Figure 2).
In order to analyze the influence of medication on
serum S100B levels in schizophrenia there are generally two
options. Firstly, one might compare medicated and unmedicated
patients in a cross-sectional approach. Secondly, meta-analyzing
longitudinal studies enables investigating treatment effects in
the same cohort. Comparing studies including only medicated
(n = 249) to those including only unmedicated patients (n =
244) in a subgroup meta-analysis, there was no significant
difference in effect sizes between those two groups (p = 0.927,
Figure 3). Note that studies including both medicated and
unmedicated patients without analyzing them separately had to
be excluded from this analysis. There were, however, high levels
of heterogeneity even within the two subgroups (see Table 1)
as well as a relatively small number of studies in the subgroups
(seven studies for medicated, nine for unmedicated subjects, see
Figure 3).
Investigating effects of treatment with the longitudinal
approach, thus meta-analyzing treatment studies within the
same subjects (Figure 4), we found no significant difference in
treatment effects between patient groups undergoing medication
for 6 vs. for 12 weeks (p = 0.281). Neither did the overall
treatment effect size (g = −0.135, S100B levels lower after
treatment than before) reach significance (p = 0.176) in a mixed
effects analysis.
Meta-Regression
The meta-regression of S100B serum levels with clinical
parameters in schizophrenia revealed significant effects
for the covariates illness duration (βillness duration = 0.0537,
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FIGURE 2 | Forest plot for the meta-analysis of serum S100B levels in schizophrenic patients compared to healthy control subjects. Hedges’ g was
used as an estimate of effect size under a random effects model. CI, confidence interval.
FIGURE 3 | Forest plot for the meta-analysis of serum S100B levels in medicated vs. unmedicated patients in a cross-sectional design. Hedges’ g was
used as an estimate of effect size under a random effects model. CI, confidence interval.
p = 0.01), bias index (βbias index = 0.3023, p = 0.001) as
well as PANSS total (βPANSS total = −0.0435, p = 0.001),
positive (βPANSS positive = −0.1273, p = 0.02) and general
psychopathology (βPANSS general = −0.0965, p < 0.001)
scores, but not for any of the other regressions calculated
(see Table 2, Figure 5).
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FIGURE 4 | Forest plot for the meta-analysis of serum S100B levels before vs. after neuroleptic/antipsychotic treatment in longitudinal studies.
Hedges’ g was used as an estimate of effect size under a random effects model. Effect sizes are shown for each treatment duration separately as well as the overall
effect of treatment regardless of duration. CI, confidence interval.
TABLE 2 | Results of simple meta-regression of covariates with serum
S100B effect size.
Covariate Number of Coefficient (β) r2 p
studies
Mean age 19 0.0573 0.52 0.0026
Illness duration 16 0.0537 0.46 0.0086
Mean age at onset 16 0.1022 0 0.2329
Male-to-female ratio 19 0.0161 0 0.8444
PANSS total score 11 −0.0435 0.82 0.0014
PANSS positive 8 −0.1273 0.55 0.0228
PANSS negative 9 −0.0856 0 0.2766
PANSS general 7 −0.0965 1 0.0008
BPRS score 6 0.0339 0.25 0.1859
Bias index 19 0.3023 0.61 0.0010
Note: BPRS, Brief Psychiatric Rating Scale; PANSS, Positive And Negative
Syndrome Scale.
Subsequent multiple meta-regression of the PANSS subscores
was then performed to obtain an impression of the influence of
the individual factors while partialling out the impact of the other
subscales. Results are illustrated in Table 3.
A multiple meta-regression analysis including the factors
illness duration and age at onset revealed a significant influence
of the former (βillness duration = 0.0538, p < 0.01), while the latter
failed to meet significance criteria (βage at onset = 0.0997, p = 0.12,
n.s., see Table 3). Amodel including the positive and the negative
subscale showed a significant effect of the PANSS positive score
on predicting effect sizes in the individual studies, whereas
testing the influence of the negative subscale as a predictor
while holding PANSS positive constant did not lead to this
factor becoming significant (βPANSS positive = −0.1203, p = 0.01,
βPANSS negative = −0.0797, p = 0.13, n.s.). A model including
the positive and the general subscale revealed the factor general
psychopathology to remain significant (βPANSS general = −0.0911,
p < 0.01) while the positive subscale lost its predictive value
(βPANSS positive = −0.0127, p = 0.69, n.s.). No individual factor
remained significant in an analysis including all three subscales
(βPANSS positive = −0.0038, p = 0.96, n.s., βPANSS negative = 0.0095,
p = 0.91, n.s., βPANSS general =−0.0977, p = 0.16, n.s.).
DISCUSSION
Our comprehensive meta-analysis, including 19 original studies
with 766 patients and 607 healthy control subjects revealed
elevated levels of the glial marker protein S100B in serum in
schizophrenia, which is related to illness duration and to clinical
symptomatology. In the following we want to discuss these
findings in detail.
Serum S100B is Increased in
Schizophrenia without Influences
of Medication
Regarding the comparison of patient vs. control group, the
outcome of a Hedges’ g of 0.925 constitutes a rather strong effect
(Figure 2), thus confirming the result of previous meta-analyses
indicating higher levels of S100B in serum of patients compared
to healthy control subjects (Schroeter et al., 2003; Schroeter and
Steiner, 2009; Aleksovska et al., 2014). Testing the influence of
risk of bias on effect size by meta-regression of a measure of bias
published in Polyakova et al. (2015), we found that higher S100B
effects were related to a lower likelihood of bias, as indicated
by a high score in this bias index (Figure 5). Thus, studies
with higher methodological quality tend to show higher S100B
serum levels in patients compared to healthy controls, suggesting
that this effect is not overestimated. Differences in included
studies in comparison to the meta-analysis by Aleksovska et al.
(2014) are related to more conservative inclusion criteria in
our study, in particular the stricter age-matching of control
cohorts.
Medication effects were investigated with two complementary
approaches in our meta-analysis. Both the cross-sectional
and the longitudinal approach revealed no significant
effect of neuroleptic treatment on serum S100B levels in
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FIGURE 5 | Results of a meta-regression analysis investigating the influence of duration of illness, age at onset, PANSS total and positive score,
PANSS general subscale score and bias index on effect size of serum S100B levels in schizophrenia. PANSS, Positive And Negative Syndrome Scale.
schizophrenia. Regarding the cross-sectional analysis one
has to take into account that the lack of a between-group
effect when comparing studies with only medicated to
those including only unmedicated subjects could be due
to a high heterogeneity both within and between studies
in both groups. Unmedicated subjects encompassed never-
medicated as well as patients off neuroleptics/antipsychotics
for a minimum of 1 week, whereas medicated subjects widely
differed in the type of neuroleptic/antipsychotic drug they were
administered. Additionally, information on further psychoactive
co-medication or either licit (tobacco or alcohol) or illicit drug
use was not consistently supplied across studies. Similarly,
the longitudinal approach also included a mixture of drug-
naïve patients and such with prior neuroleptic medication but
drug-free at the time of investigation. Subsequent treatment
likewise consisted of different types of neuroleptics. Moreover,
only six longitudinal studies were available for meta-analysis,
hence lack of statistical power might be an important factor
to be considered here. Accordingly, future better-controlled
studies are required to disentangle the impact of medication and
disease.
In sum, our meta-analyses indicate higher S100B serum
levels in schizophrenia when compared to control subjects
without any evidence for treatment effects to date. Our
results confirm elevated S100B serum levels as an indicator of
glial pathology in schizophrenia (Rothermundt et al., 2004a;
Schroeter et al., 2009; Aleksovska et al., 2014), although
this finding does not seem to be disease-specific, i.e., serum
S100B seems to be elevated also in other psychiatric disorders
such as mood disorders (Schroeter and Steiner, 2009), as
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TABLE 3 | Results of multiple meta-regression analysis with serum S100B
effect size.
Covariate Number of Coefficient (β) r2 of p
studies combined
model
Illness duration 16 0.0538 0.54 0.0062
Mean age at onset 0.0997 0.1171
PANSS positive 7 −0.0038 0.98 0.9635
PANSS negative 0.0095 0.9128
PANSS general −0.0977 0.1561
PANSS positive 8 −0.1203 0.80 0.0136
PANSS negative −0.0797 0.1316
PANSS positive 7 −0.0127 1.00 0.6925
PANSS general −0.0911 0.0077
Illness duration 9 0.0446 0.96 0.0685
PANSS total −0.0284 0.0606
Note: BPRS, Brief Psychiatric Rating Scale; PANSS, Positive And Negative
Syndrome Scale.
shown in recent meta-analyses (Schroeter et al., 2008, 2010,
2011, 2013). In contrast to antidepressant drugs, where S100B
serum levels have been discussed as indicators/biomarkers
for successful treatment (Schroeter et al., 2008), as of yet
there is no meta-analytic evidence for serum S100B being
related to treatment success of neuroleptics/antipsychotics in
schizophrenia.
Illness Duration and Clinical Symptoms are
Correlated with Serum S100B Levels in
Schizophrenia
There was a strong positive correlation between effect size
of S100B with duration of illness, whereas the correlation
analysis with age at onset did not show significant effects.
This analysis included 16 original studies, and accordingly, has
to be regarded as a highly consistent and relevant finding.
A multiple meta-regression analysis including illness duration
and age at onset confirmed the impact of the first factor
on serum S100B in schizophrenia (Table 3). Although effect
sizes of serum S100B levels also correlated with mean age
of schizophrenia subjects (Table 2), this effect seems to
be related to illness duration (rmean age/illness duration = 0.96,
p < 0.001; correlation according to Pearson, two-tailed p)
since S100B effects sizes were calculated by comparing
schizophrenia subjects to age-matched control subjects, hence
excluding any impact of age per se. Therefore, mean age was
excluded from the aforementioned multiple meta-regression
analysis.
Contrary to earlier studies we observed a significant
correlation of serum S100B effect size with PANSS total, positive
and general psychopathology, yet not with PANSS negative
scores (Rothermundt et al., 2001, 2004b; Schroeter et al., 2003;
Schmitt et al., 2005). A high intercorrelation of the positive
subscale with the total score also suggests that the effect of
the PANSS total score might be driven by high scores in the
positive subscale (rPANSS total/PANSS positive = 0.83, p = 0.01). An
additional multiple meta-regression analysis (Table 3) including
positive and negative symptoms as measured with the PANSS
confirmed the impact of PANSS positive scores on serum S100B
levels, whereas the same analysis with the PANSS general score
included additionally revealed no significant result.
While the correlation of S100B levels with the general
psychopathology subscale was even stronger than with the
positive subscale, it has to be noted that only seven studies
contributed to the former, whereas there was one more for the
latter. Furthermore, as illustrated in Figure 5, two studies seem
to predominantly drive this effect, with the other five being
distributed rather evenly. Thus, at the moment it is not possible
to estimate whether there truly is any relation of the general
psychopathology scale to S100B levels.
Seeing that the recommended minimum number of original
studies for meta-regression to gain validity has been estimated
at around ten (Borenstein et al., 2009), these subscale analyses
for positive, negative, and general symptoms so far remain highly
speculative as they all include less than ten studies (Table 2). The
analysis for the PANSS total score on the other hand seems to be
more statistically reliable with eleven studies included, and not
prone to the strong effects of multicollinearity observed between
the individual subscores.
In conclusion, duration of illness seems to influence serum
S100B levels in schizophrenia patients, with larger differences
between patients and control subjects the longer the disorder has
been present on average. With regards to psychopathology, the
PANSS total score and with a lower evidence, the PANSS positive
symptom subscale as well as the PANSS general psychopathology
score are inversely correlated with effect size, i.e., the more (total,
positive or general) symptoms, the smaller the difference in
S100B between patients and control subjects.
One might ask whether these effects, in particular influences
of illness duration and clinical scores on serum S100B effect sizes,
might be interrelated. Indeed, illness duration was negatively
correlated with clinical symptoms as measured with the relevant
PANSS scores across studies (rillness duration/PANSS total = −0.73,
p = 0.03, rillness duration/PANSS positive = −0.82, p = 0.03,
rillness duration/PANSS general = −0.91, p = 0.03, in contrast
rillness duration/PANSS negative = −0.15, p = 0.72). Accordingly,
studies examining patients with longer duration of illness
find lower psychopathology scores, which might be related to
medication/treatment effects in the long-term or disease course
itself. Multiple meta-regression including both duration of illness
and the most reliable measure for clinical symptoms, the PANSS
total score, led to both factors just narrowly missing significance,
indicating some shared variance (Table 3).
The relative increase of serum S100B levels in the course
of schizophrenia could be explained with dynamic glial
alterations in the course of the disease. Both astrocytes
and oligodendrocytes contain S100B, which may be released
under conditions of reduced energy supply or cell damage
(Steiner et al., 2007, 2008). Accordingly, in the context of
schizophrenia, both dystrophy and swelling of astrocytes were
found to progress with the duration of illness in an electron
microscopic study (Kolomeets and Uranova, 2010; Bernstein
et al., 2015). Moreover, oligodendrocyte-related disturbances
of cerebral connectivity (Yao et al., 2015) and white matter
pathology also progress over time, including a disturbed
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connectome organization which has been related to longitudinal
changes in general functioning in schizophrenia (Whitford
et al., 2007; Collin et al., 2015). Decreases in white matter
volume are more pronounced than gray matter changes in the
course of schizophrenia (Andreasen et al., 2011). Furthermore,
in this study, white matter changes were also associated
with the psychotic but not the negative symptom dimension.
Interestingly, serum S100B correlates with white and not gray
matter parameters in healthy subjects (Streitbürger et al.,
2012).
Alternatively, these findings might be related to treatment, as
patients taking neuroleptic/antipsychotic medication for longer
time tend to be less symptomatic compared to recent-onset
schizophrenia, thus showing lower PANSS scores but possibly
also elevated S100B levels with longer duration of illness.
However, so far no significant medication effect could be
detected in our meta-analyses of either the cross-sectional or the
few longitudinal studies, and tendencies so far seem to show a
reduction of serum S100B through medication (Rothermundt
et al., 2001, 2004b; Ling et al., 2007; Sarandol et al., 2007;
Schroeter et al., 2009; Steiner et al., 2009, 2010c; de Souza et al.,
2009; Nardin et al., 2011).
A possible explanation integrating all these findings
could be a mediating effect of BMI, as long-term use of
neuroleptics/antipsychotics tends to lead to weight gain, and
adipocytes are among the cell types secreting S100B. This
explanation is well in line with results found by Steiner et al.
(2010a,b, 2014), also linking this effect to changes in insulin
metabolism (Steiner et al., 2010d). Alternatively, the progression
of the schizophrenic disorder itself could cause metabolic
changes leading to both weight gain and altered S100B secretion
(see Steiner et al., 2014). In fact, Steiner et al. (2010d), found that
in their group of patients, schizophrenia was generally associated
with impaired glucose tolerance, irrespective of medication
status or BMI.
Unfortunately, the influence of BMI as a covariate could not
yet be investigated in this meta-analysis, as there are currently
only three studies (Qi et al., 2009; Steiner et al., 2009; O’Connell
et al., 2013) offering that kind of information. Other correlates of
adipocyte or insulin metabolism so far have only been published
for the patient group of Steiner et al. (2009). Consequently,
although metabolic changes associated with schizophrenia seem
to offer a plausible explanation for the meta-regression findings
in this analysis, further research in that direction will be needed
to elucidate the exact determinants of serum S100B levels as well
as the precise function of this protein in schizophrenia.
CONCLUSION
In summary, our comprehensive meta-analysis including
19 original studies with a total of 766 patients and 607 healthy
control subjects confirms higher values of the glial serummarker
protein S100B in schizophrenia compared to control subjects.
Meta-regression analyses revealed significant effects of illness
duration, with higher S100B serum levels in the disorder’s
course, and an impact of clinical symptomatology, in particular
a negative correlation of the total score of the PANSS with serum
S100B levels in schizophrenia. Accordingly, results are in line
with glial pathology in schizophrenia that is modulated by illness
duration and related to clinical symptomatology. Further studies
are needed to investigate mechanisms and mediating factors for
these findings, and replicate findings for subscales measuring
clinical psychopathology by including more studies.
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